Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Thomas Anderson, Rotem Petranker, Daniel Rosenbaum, et al.
Psychopharmacology (2019) Vol. 236, Iss. 2, pp. 731-740
Closed Access | Times Cited: 133

Showing 26-50 of 133 citing articles:

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1521-1532
Closed Access | Times Cited: 53
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1316-1322
Open Access | Times Cited: 53
Psychedelic Research and the Need for Transparency: Polishing Alice’s Looking Glass
Rotem Petranker, Thomas Anderson, Norman A. S. Farb
Frontiers in Psychology (2020) Vol. 11
Open Access | Times Cited: 52
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 52
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
Josephine Marschall, George Fejer, Pascal Lempe, et al.
Journal of Psychopharmacology (2021) Vol. 36, Iss. 1, pp. 97-113
Open Access | Times Cited: 52
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Kate Corrigan, Maeve Haran, Conor McCandliss, et al.
Irish Journal of Medical Science (1971 -) (2021) Vol. 191, Iss. 3, pp. 1385-1397
Open Access | Times Cited: 46
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Psychotherapy with Psilocybin for Depression: Systematic Review
Jonathan Joseph Dawood Hristova, Virtudes Pérez‐Jover
Behavioral Sciences (2023) Vol. 13, Iss. 4, pp. 297-297
Open Access | Times Cited: 20
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing
Balázs Szigeti, David Nutt, Robin Carhart‐Harris, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats
Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff, et al.
Molecular Psychiatry (2023) Vol. 28, Iss. 9, pp. 3829-3841
Open Access | Times Cited: 17
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Keeping the promise: a critique of the current state of microdosing research
Rotem Petranker, Thomas Anderson, Emily C. Fewster, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 6
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Genís Oña, José Carlos Bouso
Neuroscience & Biobehavioral Reviews (2020) Vol. 119, pp. 194-203
Closed Access | Times Cited: 44
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention
Rotem Petranker, Thomas Anderson, Larissa J. Maier, et al.
Journal of Psychopharmacology (2020) Vol. 36, Iss. 1, pp. 85-96
Open Access | Times Cited: 39
Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study
Michiel van Elk, George Fejer, Pascal Lempe, et al.
Psychopharmacology (2021) Vol. 239, Iss. 6, pp. 1705-1720
Open Access | Times Cited: 38
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Nicole Fadahunsi, Jens Lund, Alberte Wollesen Breum, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 24
Side Effects of Microdosing Lysergic Acid Diethylamide and Psilocybin: A Systematic Review of Potential Physiological and Psychiatric Outcomes
Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz, et al.
Neuropharmacology (2025), pp. 110402-110402
Closed Access
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS)
Paweł Holas, Justyna Kamińska, Marcin Zajenkowski
Dialogues in Clinical Neuroscience (2025) Vol. 27, Iss. 1, pp. 11-21
Open Access
Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?
Iva Totomanova, Eline Haijen, Petra P.M. Hurks, et al.
International review of neurobiology (2025)
Closed Access
Feel connected to create: Self-reported psychedelic drug users exhibit higher sense of connectedness and better divergent thinking skills compared to non-users
Christian Rominger, Carolina Subow
PLoS ONE (2025) Vol. 20, Iss. 4, pp. e0320755-e0320755
Open Access
Rapid-Acting Antidepressants
Jeffrey M. Witkin, Daniel E. Knutson, Gabriel J. Rodriguez, et al.
Current Pharmaceutical Design (2018) Vol. 24, Iss. 22, pp. 2556-2563
Closed Access | Times Cited: 39
Trends in the Top-Cited Articles on Classic Psychedelics
David W. Lawrence, Bhanu Sharma, Roland R. Griffiths, et al.
Journal of Psychoactive Drugs (2021) Vol. 53, Iss. 4, pp. 283-298
Closed Access | Times Cited: 29
Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality
Ivana Solaja, Kate Haldane, Natasha L. Mason, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 158, pp. 105570-105570
Closed Access | Times Cited: 4
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Sam Gandy
Journal of Psychedelic Studies (2019) Vol. 3, Iss. 3, pp. 280-287
Open Access | Times Cited: 33

Scroll to top